Clostridioides difficile infection

The National Quality Forum (NQF) Endorses Centers for Disease Control and Prevention's (CDC) New Blood Culture Contamination Quality Measure

Retrieved on: 
Wednesday, February 8, 2023
Consensus, Acute kidney injury, Centers for Medicare & Medicaid Services, Blood culture, Patient safety, Hospital, Blood, Korea Disease Control and Prevention Agency, CSAC, Clinical and Laboratory Standards Institute, Patient, Fungal infection, CLSI, Safety, Magnolia, Sepsis, Medicare, Bloodstream infections, Infection, Risk, CDC, Laboratory, Clinical, Guideline, Invention, CMS, Antimicrobial, Clostridioides difficile infection, NQF, Nursing, Vaccine, Pharmaceutical industry

SEATTLE, Feb. 8, 2023 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) family of products, today commended the NQF Consensus Standards Approval Committee (CSAC) for its formal endorsement of the new CDC Quality Measure 3658, entitled: Adult Blood Culture Contamination Rate; A national measure and standard for clinical laboratories and antibiotic stewardship programs.1

Key Points: 
  • The NQF's recent endorsement of this important new measure reflects the diagnostic significance of blood cultures in the detection of bloodstream infections, including sepsis.
  • The planned use of this measure is to support hospital-specific quality improvement projects, public reporting, and regulatory and accreditation programs associated with the suspected sepsis patient population.
  • Standardizing how blood culture contamination is defined, tracked, monitored, and reported will benefit millions of patients and save our healthcare system billions of dollars under the new standard of care.
  • The CDC Guidelines also provided eight evidence-based practices for reducing blood culture contamination rates, including the use of Initial Specimen Diversion Devices® that divert the initial 1 to 2 mL of potentially contaminated blood prior to blood collection.6,7

Fzata Raising Series A For New Oral Biologics Platform Modality

Retrieved on: 
Thursday, January 26, 2023
Inflammation, Clostridioides difficile, Inflammatory Bowel Diseases, SEED, Therapy, Diabetes, Clostridioides difficile infection, NIH, BIO, Visceral pain, Ulcerative colitis, Pharmaceutical industry, IND

HALETHORPE, Md., Jan. 26, 2023 /PRNewswire/ -- Fzata, Inc., announces that it is raising series A funding for its first-in-class Bioengineered Probiotic Yeast Medicines (BioPYM™) platform.

Key Points: 
  • HALETHORPE, Md., Jan. 26, 2023 /PRNewswire/ -- Fzata, Inc., announces that it is raising series A funding for its first-in-class Bioengineered Probiotic Yeast Medicines (BioPYM™) platform.
  • This is a novel oral administration modality for biologics.
  • Fzata's vision is to replace needle administration of biologics with a capsule for suffers of gastrointestinal disorders.
  • Dr. Zhiyong Yang, President and CEO of Fzata, commented: "Fzata has been honored to be a SEED company with the NIH.

Large-scale, peer-reviewed study quantifies multiple devastating patient harms associated with blood culture contamination and most significantly, a 74% increase in risk of in-hospital patient mortality

Retrieved on: 
Tuesday, January 24, 2023
BMI, Safety, Vancomycin, University, Blood culture, University of Arkansas, Medical Center, Invention, Emergency department, Medical director, Culture, Entrepreneurship, Associate, Infection, Fungal infection, Infection Control & Hospital Epidemiology, Hospital, Acute kidney injury, Risk factor, Patient safety, FDA, Growth, UAMS, Antimicrobial stewardship, Length of stay, Patient, Sepsis, Risk, Body mass index, Mortality, HAI, Magnolia, Clostridioides difficile infection, CDI, Medicine, Pharmaceutical industry, Nursing

SEATTLE, Jan. 24, 2023 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®), the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy1, today shared the publication of recent clinical results from the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas. This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.

Key Points: 
  • This four-year retrospective analysis examined the clinical and financial impacts of blood culture contamination on patient safety, outcomes, and in-hospital patient mortality.
  • Blood culture is one of the most frequently performed diagnostic tests in U.S. hospitals with an estimated 58 million tests each year.
  • However, positive blood culture results are frequently wrong, with approximately 40% of positive results returning a false-positive result due to contamination.
  • "It is imperative for hospital systems to make decreasing blood culture contamination a priority to improve safety for patients under our care.

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Retrieved on: 
Tuesday, January 24, 2023
Autism, CDI, Therapy, Clostridioides difficile infection, Patient, Ulcerative colitis, FNCH, Workforce, Research, Doctor of Philosophy, Pharmaceutical industry, Finch

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.

Key Points: 
  • SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.
  • As a result of this decision, Finch is reducing its workforce by approximately 95%.
  • Finch has a portfolio of microbiome assets including CP101, an investigational orally administered microbiome candidate with positive data from a Phase 2 placebo-controlled trial and a Phase 2 open-label trial in recurrent CDI.
  • Additionally, Finch has pre-clinical microbiome assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder.

Global Microbiome Targeting Therapeutics in Infectious Diseases Report 2022: Featuring Rebiotix, Nexbiome Therapeutics, Finch Therapeutics and Evelo Biosciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Fitness & Nutrition, Health, CDI, IO, Therapy, COVID-19, LBP, Human microbiome, Infection, FMT, Cancer, Clostridioides difficile infection, Clostridioides, Antibiotics

The "Microbiome-Targeting Therapeutics in Infectious Diseases - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiome-Targeting Therapeutics in Infectious Diseases - Thematic Research" report has been added to ResearchAndMarkets.com's offering.
  • There are currently 23 drugs in clinical development that target the microbiome for ID indications in the 7MM.
  • Ten out of the 23 drugs (43%) are in in clinical development for Clostridioides difficile infections (CDI).
  • Rebiotix Inc currently holds the most potential in the microbiome space for infectious diseases, with two drug candidates under development across 4 different indications.

Violet Defense Receiving Accreditation From American Institute of Architects

Retrieved on: 
Thursday, December 22, 2022
School, Coronavirus, Norovirus, AIA, Automation, Clostridioides difficile infection, Certification, American Institute, COVID-19, Disinfectant, MRSA, Escherichia coli, Accreditation, Severe acute respiratory syndrome coronavirus 2, Health, Atmosphere, UV, S. aureus, HVAC, Salmonella, Interior design, Sewage

With accreditation from the American Institute of Architects (AIA) in 2023, Violet Defense will create courses to educate architects on how they can incorporate UV disinfection technology into their core designs for sustainable buildings.

Key Points: 
  • With accreditation from the American Institute of Architects (AIA) in 2023, Violet Defense will create courses to educate architects on how they can incorporate UV disinfection technology into their core designs for sustainable buildings.
  • However, architects have had little guidance on how to include the technology during the design stage and face a significant hurdle.
  • "With AIA certification, we will create courses that will help architects incorporate UV disinfection technology into their designs right from the start."
  • Violet Defense technology already is in wide use nationwide, including hotels, convention centers, colleges and schools, and amateur and professional sports training facilities.

Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress

Retrieved on: 
Thursday, January 5, 2023
Bill & Melinda Gates Foundation, Lumen, ESG, GMP, Vaccine, NPJ, Tropical disease, Drug development, Research, ETEC, Bill, Clostridioides difficile infection, R, Growth, Malaria, CGMP, FDA, COVID-19, NIH, Recurrence, Nature Biotechnology, BARDA, Dietary supplement, Financial services, Pharmaceutical industry, IND

"In 2022 we experienced strong growth across all facets of our company and operations, positioning Lumen for significant events in the coming year," said Brian Finrow, co-founder and CEO of Lumen Bio.

Key Points: 
  • "In 2022 we experienced strong growth across all facets of our company and operations, positioning Lumen for significant events in the coming year," said Brian Finrow, co-founder and CEO of Lumen Bio.
  • Some aspects of 2022 progress include:
    Commercial Pipeline — An accelerating pipeline of clinical stage programs targeting prevalent, unmet needs backed by blockbuster commercial opportunities.
  • LMN-201 for prevention of C. difficile infection – LMN-201 is the world's first rationally engineered, complex biologic cocktail to enter human clinical trials.
  • LMN-301 for Covid-19 – In 2022, Lumen Bio's Covid-19 funding consortium expanded to include BARDA and the Bill & Melinda Gates Foundation .

Fzata to Pitch BioPYM™ Platform at the Biotech Showcase™ 2023

Retrieved on: 
Tuesday, December 20, 2022
Needle, CDI, Diabetes, Obesity and Metabolism, Inflammatory Bowel Diseases, Investment, IBD, Diabetes, Conference, Inflammation, Ulcerative colitis, Clostridioides difficile infection, IND, Therapy, Degenerative disease, Visceral pain, Infection, Research, Cancer, NIH, Pharmaceutical industry, MD

Fzata will pitch live Wednesday, January 11 at 4:15, Room Franciscan B, Hilton San Francisco Union Square.

Key Points: 
  • Fzata will pitch live Wednesday, January 11 at 4:15, Room Franciscan B, Hilton San Francisco Union Square.
  • Fzata will also attend the virtual event January 18-19, 2023.
  • Dr. Zhiyong Yang, President and CEO of Fzata, commented, "Our vision is to expand patient access to therapeutic biologics.
  • About Fzata, Inc.: Fzata ( www.Fzata.com ) is a near-clinical stage biopharmaceutical company, developing oral live biologic-based preventive and therapeutic medicines.

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

Retrieved on: 
Thursday, December 15, 2022
Conference, Immunotherapy, Annual report, Clostridioides difficile infection, Genetic engineering, Mortality, Entrepreneurship, Biotechnology, Government, SAB, Degenerative disease, J. P. Morgan, Probability, United States Department of Defense, Type 1, MD, Form 10-K, Infection, Pandemic, IND, Patent, Clostridioides difficile (bacteria), Patient, Showcase, Pharmaceutical industry, Vaccine

The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.

Key Points: 
  • The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
  • Alexandra Kropotova, MD, Executive Vice President, and Chief Medical Officer of SAB Biotherapeutics, will present at the Showcase on Tuesday, January 10 at 2:30pm PT.
  • SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.
  • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .

SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

Retrieved on: 
Wednesday, December 7, 2022
Immunotherapy, Annual report, Clostridioides difficile infection, Genetic engineering, Mortality, Warrant, Government, SAB, Degenerative disease, Probability, United States Department of Defense, Type 1, Form 10-K, Infection, Arcadia, Clostridioides, Pandemic, IND, Patent, United States securities regulation, Clostridioides difficile (bacteria), Patient, Security (finance), Vaccine, Pharmaceutical industry

Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.

Key Points: 
  • Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.
  • The aggregate gross proceeds from the offering are approximately $7.9 million, based on the offering price of $1.08 which was the 5-day average closing price ending December 5, 2022, for each share of the Company's common stock plus one Warrant.
  • The Company expects to use net proceeds from the private placement to advance the Company’s pipeline of its first-in-class product candidates for Clostridioides difficile (C.
  • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .